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Abstract
Background: Ambient air pollution (AAP) may be associated with increased risk for Pneumocystis pneumonia
(PCP). The mechanisms underlying this association remain uncertain.
Objectives: To determine if real-life exposures to AAP are associated with suppressed IgM antibody responses to P.
jirovecii in HIV-infected (HIV+) patients with active PCP, and to determine if AAP, mediated by suppressed serologic
responses to Pneumocystis, is associated with adverse clinical outcomes.
Methods: We conducted a prospective cohort study in HIV+ patients residing in San Francisco and admitted to San
Francisco General Hospital with microscopically confirmed PCP. Our AAP predictors were ambient air concentrations
of particulate matter of < 10 µm in diameter (PM10) and < 2.5 µm in diameter (PM2.5), nitrogen dioxide (NO2), ozone
(O3), and sulfur dioxide (SO2) measured immediately prior to hospital admission and 2 weeks prior to admission. Our
primary outcomes were the IgM serologic responses to four recombinant P. jirovecii major surface glycoprotein (Msg)
constructs: MsgC1, MsgC3, MsgC8, and MsgC9.
Results: Elevated PM10 and NO2 exposures immediately prior to and two weeks prior to hospital admission were
associated with decreased IgM antibody responses to P. jirovecii Msg. For exposures immediately prior to admission,
every 10 µg/m3 increase in PM10 was associated with a 25 to 35% decrease in IgM responses to Msg (statistically
significant for all the Msg constructs), and every 10 ppb increase in NO2 was associated with a 19-45% decrease in
IgM responses to Msg (statistically significant for MsgC8 and MsgC9). Similar findings were seen with exposures two
weeks prior to admission, but for fewer of the Msg constructs.
Conclusions: Real life exposures to PM10 and NO2 were associated with suppressed IgM responses to P. jirovecii
Msg in HIV+ patients admitted with PCP, suggesting a mechanism of immunotoxicity by which AAP increases host
susceptibility to pulmonary infection.
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Introduction
Greater than three million deaths per year are attributable to
ambient air pollution (AAP), and AAP is the 9th leading factor
contributing to worldwide burden of disease according to the
2010 Global Burden of Disease Study [1]. AAP is well
established as a risk factor for a wide array of cardiopulmonary
diseases, and there is emerging data that it is associated with
pulmonary infections. For instance, a number of observational
studies have found AAP to be associated with increased
emergency department visits and hospital admissions for
community acquired pneumonia [2-12]. AAP may also
contribute to the morbidity of other pulmonary infections,
although data in this area is limited. It is also unclear if the
effects of AAP are present and perhaps magnified in
immunosuppressed populations, such as those with HIV, who
are already at increased risk for pulmonary infections [13,14].
Pneumocystis pneumonia (PCP) continues to contribute to
substantial morbidity and mortality in immunosuppressed
children and adults worldwide [15], and a better understanding
of environmental risk factors contributing to PCP incidence and
disease severity is needed. In one recent case-crossover study
Djawe et al. observed an association between high AAP levels
and increased hospital admissions for PCP among HIV-
infected (HIV+) patients [16]. The underlying mechanisms for
this increased susceptibility for PCP hospitalizations with AAP
exposure remain unknown, but mechanisms of AAP induced
immunotoxicity seem most plausible. As Pneumocystis is
extremely difficult to grow in culture, we have developed an
enzyme-linked immunosorbent assay (ELISA) using
recombinant Pneumocystis jirovecii major surface glycoprotein
(Msg) to assess serologic responses to P. jirovecii [17-21]. We
selected this assay for the current study because it has been
validated in diverse cohorts worldwide [22,23] and has been
informative in assessing immunologic responses to
Pneumocystis in those with HIV infection [24].
The mechanisms by which ambient air pollution increases
susceptibility to pulmonary infection are not well defined. Single
pollutant controlled exposure studies using cells, animals and
human subjects have found that ambient air pollutants alter
innate lung immunity at multiple levels [25] including altered
mucociliary function [26], respiratory epithelial cell dysfunction
[27,28], impaired alveolar macrophage phagocytosis [29-32],
and surfactant protein A and D dysfunction [33]. However, the
effects of AAP on humoral immunity and serologic responses
to pulmonary infection, and the immunotoxic effects of real-life
exposures to AAP remain unclear.
To address these areas of uncertainty we proposed two
hypotheses for this study. First, real-life exposures to AAP
suppress IgM antibody responses to P. jirovecii Msg, and
second, AAP exposures, mediated by suppressed serologic
responses to P. jirovecii Msg, are associated with adverse
clinical outcomes. To test these hypotheses we conducted a
prospective cohort study of HIV+ patients residing in San
Francisco and hospitalized at San Francisco General Hospital
with confirmed PCP.
Methods
Study population
From June 2000 to September 2007 we enrolled consecutive
HIV+ adults (age > 18 years) hospitalized at San Francisco
General Hospital with suspected PCP into a longitudinal cohort
[34]. From this cohort, those with a definitive microscopic
diagnosis of PCP and residence within the San Francisco city
limits were eligible for inclusion in our prospective study. We
excluded those with prior enrollment into the cohort and those
without an available serologic specimen within 2 days of
hospital admission. Hospital admission criteria for PCP
included a supplemental oxygen requirement and/or poor oral
intake, while discharge criteria included oxygen saturations >
90% while breathing room air and adequate oral intake.
Clinical and demographic data collection
After obtaining written, informed consent, we administered a
standardized questionnaire to all participants, followed them
throughout their hospitalization, and performed chart
abstraction upon discharge from the hospital to obtain the
following clinical data: age, sex, race/ethnicity, residential
address, cigarette smoking status, prior history of PCP,
antiretroviral medication and PCP prophylaxis, CD4 cell count,
HIV viral load, length of hospital stay, admission to intensive
care unit, intubation, and in-hospital mortality.
Ambient air pollutant measurements
We evaluated criteria pollutants most implicated in
cardiopulmonary disease: particulate matter of < 10μm (PM10)
and < 2.5μm in diameter (PM2.5), nitrogen dioxide (NO2), ozone
(O3), and sulfur dioxide (SO2). The Bay Area Air Quality
Management District monitors air pollutant concentrations in
San Francisco at a centrally located monitoring station on 10
Arkansas Street for U.S. Environmental Protection Agency
(EPA) regulatory compliance purposes. We used these
publically available data to assign AAP exposures for each
participant immediately prior to hospital admission and 2 weeks
prior to admission. We chose these two exposure periods a
priori based on biological plausibility of the timing of these
exposures being associated with serologic responses to P.
jirovecii at admission. For each period, we calculated the
average exposure over 3 days. For the period immediately
prior to admission, we averaged exposures from the day of
admission, 1 day prior to admission, and 2 days prior to
admission (days 0, -1, and -2). For the period 2 weeks prior to
admission, we averaged exposures from days 14, 15, and 16
prior to admission (days -14, -15, and -16). The air pollutant
metrics used in the analysis were as follows: daily mean PM10
and PM2.5 concentrations (μg/m3), daily maximum 1-hour NO2
concentrations in parts per billion (ppb), daily maximum 8-hour
O3 concentrations (ppb), and daily maximum 1-hour SO2
concentrations (ppb).
Recombinant antigens
Using a λgt11 clone of Msg gene obtained from human
infected lung as our template, we amplified the gene segment
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Msg2015-3332 (subscript denotes number of nucleotides) using
PCR with AmpliTaq enzyme (Applied Biosystems, Carlsbad,
CA, USA) [18]. We then inserted the amplified gene segment
into the pET30 E. coli expression system (Novagen, Madison,
WI, USA) to generate MsgC1 recombinant protein. We purified
this protein by affinity chromatography. Using a similar process
and P. jirovecii-infected human lung as our template, we
generated MsgC3, MsgC8, and MsgC9 recombinant proteins
from the same gene region as for MsgC1 [20]. These MsgC
constructs are representative of the most antigenically
conserved carboxyl-terminus region of the major surface
glycoprotein [17].
IgM ELISA
We collected serum from each subject within two days of
hospital admission and stored the sera at -80°C until shipment
to University of Cincinnati for IgM ELISA analysis. Using a
previously described protocol developed in our lab [21], we
measured serum IgM responses to the four recombinant MsgC
constructs; MsgC1, MsgC3, MsgC8, and MsgC9. We tested
subject serum specimens and standard reference sera against
the recombinant Msg constructs, using phosphate-buffered
saline (PBS) without Msg as the negative control. We corrected
the reactivity of each serum specimen to Msg by subtracting
the reactivity of each serum specimen to PBS (mean optical
density (OD) with Msg – mean OD without Msg) and quantified
the results using methods described by Bishop and Kovacs
[35]. We prepared a standard serum with specificity for each
Msg construct by mixing the sera from 4 to 6 specimens with
high reactivity for the specific construct. We selected these
specimens from banks of sera from blood donors and HIV+
patients. The standard pool for each Msg construct was
defined as having a value of 100 U in 100 μl of a 1:100 dilution.
We used the same standard pools throughout the study. From
the standard pool, we generated a standard curve for each
Msg construct on each day the assay was used. We used this
curve to calculate the units of reactivity to the Msg construct.
We diluted test serum samples at 1:100 to fit the linear portion
of the standard curves. Taking into account the dilution, we
then calculated units of reactivity.
Ethics approval
The study was approved by the institutional review boards at
the University of California San Francisco and the University of
Cincinnati.
Statistical analysis
We evaluated associations between ambient air pollutant
concentrations and IgM antibody responses to Msg constructs
using multivariable tobit regression analysis for left censored
data. Our predictors were exposures to PM10, PM2.5, NO2, O3,
and SO2. Our primary outcome variables were log-transformed
serum IgM antibody levels (in units of reactivity) to each Msg
construct (MsgC1, MsgC3, MsgC8, and MsgC9). We log-
transformed outcome variables to best conform to regression
model assumptions. We tested for the effect modification of
CD4 cell count and active cigarette smoking using interaction
terms in the tobit regression analysis. We selected these
variables as potential effect modifiers based on prior literature
[24,36] and the biologic plausibility of their interactions with air
pollutants in their associations with IgM responses to Msg
constructs. Our pre-specified criteria for reporting effect
modification were a p < 0.20 and a difference between stratum
specific regression coefficients of at least 20%. We scaled and
exponentiated regression coefficients to express logged
outcomes as percent change in IgM response to each Msg
construct per 10 unit increase in air pollutant concentration. We
also used multivariable tobit regression analysis to evaluate the
associations between clinical factors (CD4 cell count, viral load,
and active cigarette smoking) and IgM responses, adjusting for
a priori selected potential confounders (PM10, NO2, smoking,
and CD4 cell count).
We evaluated associations between air pollutant (PM10,
PM2.5, NO2, O3, and SO2) concentrations and clinical outcomes
using multivariable linear regression for the continuous
outcome (length of hospital stay) and logistic regression for the
binary outcomes (ICU admission, intubation, and in-hospital
mortality), evaluating for effect modification of log-transformed
CD4 cell count and active cigarette smoking as detailed above.
To evaluate the association of IgM responses with clinical
outcomes, we used linear regression for the continuous
outcome (length of hospital stay) and logistic regression for the
binary outcomes (ICU admission, intubation, and in-hospital
mortality), adjusting for log-transformed CD4 cell count, active
cigarette smoking, and PCP prophylaxis as a priori selected
potential confounders. Finally, we performed a mediation
analysis to determine the indirect effects of IgM responses on
clinical outcomes compared with the direct effects of air
pollutants on clinical outcomes.
Results
Subjects and ambient air pollution
We enrolled 283 consecutive HIV+ patients with suspected
PCP into the larger cohort study. A definitive microscopic
diagnosis of PCP was made in 180 of these patients, 162 of
whom were being enrolled into the cohort with PCP for the first
time (Figure 1). Of these, 88 subjects with PCP had serum
available within 2 days of admission on which IgM serologic
analysis was performed. The majority were male (n=77, 88%),
white (n=48, 55%), and active cigarette smokers (n=59, 67%)
(Table 1). Only 10 (11%) were taking antiretroviral therapy
(ARV) and eight (9%) taking PCP prophylaxis at the time of
admission. The median CD4 cell count was 33 cells/μl
(interquartile range 10-77 cells/μl) and the mean log HIV RNA
level was 11.3 copies/ml (standard deviation ± 2.0 copies/ml),
reflecting a severely immunosuppressed cohort with
uncontrolled viremia. Overall, nine patients required ICU
admission (10%) and four (5%) died during the hospitalization.
Among first-time enrollees with confirmed PCP (n=162), we
compared those patients excluded (n=74) to those included in
the study (n=88) and found no statistically significant
differences in baseline clinical characteristics or clinical
outcomes (data not shown).
All study participants resided within the San Francisco city
limits. Specific addresses were available for 65 subjects (74%)
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(Figure 2). All of these resided within 9 km of the monitoring
station, with the majority (n=36, 55%) residing within a 3km
radius of the station. Three-day average exposures to ambient
air pollutants immediately prior to and 2 weeks prior to hospital
admission varied considerably over the study period (Figures 3,
4), and were much less than the maximum allowable
concentrations as defined by National Ambient Air Quality
Standards (NAAQS) (Table 2). SO2 concentrations were
particularly low throughout the study period.
Association between AAP and IgM
Elevated 3-day average ambient air concentrations of PM10
and NO2 immediately prior to hospital admission were
associated with decreased IgM responses to all of the analyzed
Msg constructs (Table 3). For every 10 μg/m3 increase in PM10
there was a 25% decrease in IgM response to MsgC1
(p=0.002), a 35% decrease in IgM to MsgC3 (p=0.009), a 33%
decrease in IgM to MsgC8 (p=0.009), and a 25% decrease in
IgM response to MsgC9 (p=0.02). We found a similar trend for
NO2: elevated ambient air concentrations of NO2 were
associated with decreased IgM responses to all the Msg
constructs. These results reached statistical significance for
MsgC8 and MsgC9. For every 10 ppb increase in NO2 there
was a 45% decrease in IgM response to MsgC8 (p<0.001) and
a 44% decrease IgM response to MsgC9 (p<0.001). On the
Table 1. Cohort demographics and clinical characteristics
(n=88).
Characteristic n (%)*
Median age (IQR) 40 (36–46)
Male sex 77 (88)
Race/ethnicity: White 48 (55)
 Black 29 (33)
 Other 11 (13)
Active tobacco smoker 59 (67)
Homeless 16 (18)
ARV use 10 (11)
PCP prophylaxis use 8 (9)
Median CD4 cell count, cells/μl (IQR) 33 (10–77)
Log viral load ± SD 11.3 ± 2.0
Median length of stay, days (IQR)† 7 (5-10)
Admission to ICU 9 (10)
Intubation 7 (8)
In-hospital mortality 4 (5)
SD indicates one standard deviation; IQR, interquartile range; ICU, intensive care
unit; ARV, antiretroviral medication.
* Results in parentheses represent percentages unless otherwise indicated.
† Among those who survived hospitalization (n=84)
doi: 10.1371/journal.pone.0080795.t001
Figure 1.  Participant enrollment.  
doi: 10.1371/journal.pone.0080795.g001
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other hand, we found no statistically significant associations or
consistent trends between PM2.5, O3, or SO2 immediately prior
to hospital admission and IgM responses to Msg (data not
shown).
Similarly, we found that elevated 3-day average
concentrations of PM10 and NO2 in San Francisco 2 weeks prior
to admission were associated with decreased IgM responses to
MsgC, but were statistically significant for fewer MsgC
constructs (Table 3). Every 10 μg/m3 increase in PM10
predicted a 45% decrease in IgM response to MsgC3
(p=0.002) and a 34% decrease in IgM to MsgC8 (p=0.02).
Likewise, every 10 ppb increase in NO2 predicted a 41%
decrease in IgM response to MsgC3 (p=0.03), a 63% decrease
in IgM response to MsgC8 (p<0.001) and a 37% decrease in
IgM response to MsgC9 (p=0.008). As with exposures
immediately prior to admission, we did not find statistically
significant associations between PM2.5, O3, or SO2 two weeks
prior to admission and IgM responses to Msg.
Effect of cigarette smoking on the association between
AAP and IgM
Active cigarette smoking appeared to augment the
immunosuppressive effects of PM10 and NO2 exposure 2 weeks
prior to admission on IgM responses to Msg (data stratified by
smoking status not shown). For every 10 μg/m3 increase in
PM10 smokers experienced a larger decline in IgM responses to
all the constructs compared with nonsmokers. This interaction
was statistically significant for MsgC1 (p=0.04), MsgC3
(p=0.03), MsgC8 (p=0.01), and of borderline statistical
Figure 2.  Map of San Francisco showing geographic distribution of participants (n=65).*.  Legend: Blue circle— EPA
compliance air quality monitoring station; Black circle—study site (San Francisco General Hospital); Red circles—residential area
for each participant.
*Residential addresses not available for 23 subjects.
Map created at www.openstreetmap.org. Cartography licensed as CC-BY-SA.
doi: 10.1371/journal.pone.0080795.g002
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Figure 3.  Three-day average particulate concentrations immediately prior to each participant’s hospital admission.  
doi: 10.1371/journal.pone.0080795.g003
Figure 4.  Three-day average NO2, O3, and SO2 concentrations immediately prior to each participant’s hospital
admission.  
doi: 10.1371/journal.pone.0080795.g004
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significance for MsgC9 (p=0.07). A similar interaction was seen
between cigarette smoking and NO2 exposure 2 weeks prior to
admission. For every 10 ppb increase in NO2, smokers
experienced a larger decline in IgM responses to all of the Msg
constructs compared with nonsmokers. This interaction was
statistically significant for MsgC8 (p=0.03) and MsgC9
(p=0.01). Smoking, on the other hand, did not appear to be
directly associated with IgM responses in bivariate analyses
(data not shown) or after adjusting for CD4 cell count, PM10,
and NO2 (see Table 4).
Indicators of more intact immunity were associated with
increased IgM responses to Msg (Table 4). For every 50%
increase in CD4 cell count there was a 9.3% to 16% increase
in IgM responses to Msg, statistically significant for MsgC1
(p=0.02) and MsgC8 (p=0.03). On the other hand, for every
50% increase in viral load there was a non-statistically
significant decrease in IgM responses to Msg of 0.5% to 6.8%.
Association between AAP and clinical outcomes
Higher IgM responses to all the Msg constructs were
associated with shorter length of hospital stay, with each 50%
increase in IgM associated with a 0.36 to 0.90 day decrease in
length of stay (Table 5). However, this was statistically
significant only for MsgC8 (p=0.03). IgM responses to Msg
Table 2. Mean air pollution exposure concentrations for study participants compared with NAAQS (n=88).
  Pollutant concentration ± SD
Pollutant Averaging time Immediately prior to admission*      2 weeks prior to admission† NAAQS
PM10 (μg/m3) 24-hour 22.6 ± 12.9 21.6 ± 11.1 150
PM2.5 (μg/m3) 24-hour 11.3 ± 8.3 9.7 ± 7.5 35
NO2 (ppb) 1-hour 18.0 ± 10.5 15.9 ± 8.3 100
O3 (ppb) 8-hour 19.4 ± 9.9 21.0 ± 7.9 75
SO2 (ppb) 1-hour 2.1 ± 1.4 1.9 ± 1.2 75
SD indicates one standard deviation; NAAQS, National Ambient Air Quality Standards; PM10, particulate matter of < 10 µm in diameter; PM2.5, particulate matter of < 2.5 µm
in diameter; NO2, nitrogen dioxide; O3, ozone; SO2, sulfur dioxide.
* 3-day average: the day of admission, 1 day prior to admission, and 2 days prior to admission
† 3-day average: days 14, 15, and 16 prior to admission
doi: 10.1371/journal.pone.0080795.t002
Table 3. Percent change in IgM responses to Msg constructs per 10 unit increase in pollutant exposure immediately prior to
hospital admission and 2 weeks prior to admission (n=88).
  MsgC1 MsgC3 MsgC8 MsgC9
Pollutant (units)    
Exposure period (days prior to
admission)* % (95%CI) p value% (95%CI) p value% (95%CI) p value % (95%CI) p value
PM10 (μg/m3) 0 to -2 -25 (-41 to -9.4) 0.002 -35 (-61 to -9.1) 0.009 -33 (-57 to -8.5) 0.009 -25 (-46 to -4.1) 0.02
 -14 to -16 0.64 (-25 to 26) 0.96 -45 (-73 to -18) 0.002 -34 (-62 to -6.9) 0.02 -22 (-49 to 4.0) 0.10
NO2 (ppb) 0 to -2 -19 (-41 to 3.2) 0.09 -30 (-62 to 3.4) 0.08 -45 (-68 to -23) <0.001 -44 (-63 to -24) <0.001
 -14 to -16 -15 (-44 to 14) 0.30 -41 (-77 to -5.3) 0.03 -63 (-84 to -42) <0.001 -37 (-65 to -10) 0.008
Msg indicates major surface glycoprotein; CI, confidence interval; PM10, particulate matter < 10 μm in diameter; NO2, nitrogen dioxide.
* Where the day of hospital admission is indicated by “day 0”
doi: 10.1371/journal.pone.0080795.t003
Table 4. Percent change in IgM responses to Msg constructs by clinical factors (n=88).*
 MsgC1 MsgC3 MsgC8 MsgC9
Clinical factors % (95%CI) p value % (95%CI) p value % (95%CI) p value % (95%CI) p value
CD4 cell count† 12 (2.5 to 22) 0.02 9.4 (-7.3 to 26) 0.27 16 (1.5 to 31) 0.03 9.3 (-3.1 to 22) 0.14
Viral load† -2.3 (-8.0 to 3.4) 0.42 -5.9 (-15 to 3.6) 0.22 -6.8 (-15 to 1.1) 0.09 -0.5 (-8.0 to 7.0) 0.90
Active smoking# 2.3 (-58 to 62) 0.94 34 (-105 to 172) 0.63 -18 (-89 to 52) 0.61 -9.8 (-79 to 59) 0.78
* Percent change in IgM responses to Msg constructs per 50% increase in CD4, 50% increase in viral load, or for active cigarette smoking status
† Adjusted for active smoking, and PM10 and NO2 immediately and 2 weeks prior to admission
# Adjusted for CD4 cell count, and PM10 and NO2 immediately and 2 weeks prior to admission
doi: 10.1371/journal.pone.0080795.t004
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were not associated with other clinical outcomes (ICU
admission, intubation, or in-hospital mortality), nor were 3 day
average air pollution exposures immediately and 2 weeks prior
to hospital admission associated with length of stay, ICU
admission, intubation, or in-hospital mortality. Similarly, the
ambient air pollutants were not associated with other
surrogates for PCP severity, such as serum lactate
dehydrogenase (LDH). We also evaluated the association of
each ambient air pollutant with CD4 cell count as the clinical
outcome, and found no statistically significant associations
between AAP and CD4 cell count (data not shown).
Discussion
To our knowledge, this is the first prospective cohort study to
evaluate the association of ambient air pollution exposures on
serologic responses to Pneumocystis jirovecii and clinical
outcomes in HIV+ patients hospitalized with confirmed PCP.
We found that elevated ambient concentrations of PM10 and
NO2 were associated with suppressed IgM responses to
recombinant Pneumocystis major surface glycoprotein, and
that this suppression of responses may be associated with
increased length of hospital stay. Smoking appeared to
augment the immunosuppressive effects of PM10 and NO2.
PM10 and NO2 were specifically associated with suppressed
IgM responses, while PM2.5, O3, and SO2 were not. When
designing this study, we hypothesized that particulate matter
would play a significant role in altering serologic responses.
Particle deposition in the lungs is size-dependent; so-called
“fine” particles < 2.5 μm in aerodynamic diameter are inhaled to
the alveolar level, whereas somewhat larger particles from 2.5
to 10 μm in diameter (the so-called “coarse” fraction) tend to
deposit on lower airway mucociliary surfaces. As PM10 includes
both fine and coarse particles it is possible that PM10 exerts its
immunotoxicity in both airway and alveolar compartments.
Coarse particles encountering bronchus associated lymphoid
tissue, for instance, could impair antigen presenting cells,
resulting in decreased activation of the humoral immune
system and suppressed serologic responses, while fine
particles could exert immunotoxic effects on alveolar
macrophages, also resulting in impaired humoral activation.
Periodic northeasterly (“Diablo”) winds bring coarse particulate
matter of crustal origin into San Francisco. Such particulate
matter can be highly bioactive. It is possible that the greater
magnitude and variability in PM10 exposure afforded by these
local weather patterns contributed to more significant findings
for PM10 than PM2.5. Similarly, NO2 could be immunotoxic at the
alveolar level or, freely diffusible, directly toxic to B
lymphocytes. SO2 levels were clearly too low in this study to be
implicated in immunologic derangement or clinical outcomes.
San Francisco has exceedingly low SO2 pollution due to the
absence of coal-powered power plants and industry in the city
as well as California regulations requiring the use of low sulfur
fuel. Ozone concentrations are also very low in San Francisco
due to prevailing westerly winds that carry ozone precursors
from motor vehicle emissions eastward across the Bay. PM10
and NO2 levels were statistically significantly associated with
most, but not all, Msg constructs. It is unclear, for instance, why
associations between NO2 and the Msg constructs MsgC8 and
MsgC9 were more statistically significant than for MsgC1 and
MsgC3.
We selected the timing of the periods during which air
pollutant exposures were assigned to subjects based on a
priori hypothesized mechanisms of immunotoxicity. We posited
that pollutants with capacity to cross the alveolar capillary
interface into blood circulation (e.g., NO2) could have early
impact on B cell production of Pneumocystis jirovecii specific
IgM. On the other hand, we hypothesized that coarse
particulate matter, as mentioned above, would exert its effects
predominantly via impaired antigen presentation and delayed
humoral activation, an effect that might take 1 to 2 weeks to
fully realize. Supportive of these mechanistic hypotheses, we
found PM10 and NO2 exposures both immediately prior to
hospital admission and 2 weeks prior to admission to be
associated with suppressed IgM responses. These were 3-day
averaged exposures during the two periods, and it remains
unclear whether peak exposures might have independent
associations with IgM suppression. However, it would be
technically challenging to test this hypothesis in San Francisco
given the relative absence of high peak pollutant levels.
As expected, smoking appeared to interact with PM10 and
NO2 to augment suppression of serologic responses to Msg, a
finding supported by prior studies. For instance, Crothers et al.,
using similar recombinant Msg and ELISA protocols, recently
found that, among a cohort of active heavy smokers, smoking
was associated with decreased serologic responses to
Pneumocystis Msg compared with non-smoking controls [36].
Many of the pollutants in cigarette smoke are similar to those in
ambient air pollution, but at much greater concentrations.
Table 5. Change in length of hospital stay (days) per 50% increase in IgM response to Msg among those who survived to
hospital discharge (n=84).*
IgM response to Msg Length of stay
Construct Geometric mean, units (95% CI) # days (95%CI) p value
MsgC1 14.2 (11.0–18.4) -0.36 (-1.2 to 0.53) 0.42
MsgC3 3.8 (2.8–5.1) -0.53 (-1.3 to 0.21) 0.16
MsgC8 3.5 (2.6–4.6) -0.90 (-1.7 to -0.10) 0.03
MsgC9 5.7 (4.3–7.6) -0.57 (-1.3 to 0.19) 0.14
* Adjusted for log CD4 cell count, active cigarette smoking, and PCP prophylaxis.
doi: 10.1371/journal.pone.0080795.t005
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Given these properties, we expected smoking to also be
independently associated with suppressed IgM, which it was
not in this study. It was the smoking—AAP interaction, and not
smoking alone, that was associated with suppressed IgM
responses. Why we failed to find an independent effect of
smoking in this study is unclear.
Although cellular immune responses are predominantly
involved in effectively countering Pneumocystis jirovecii
infections, it is well known that humoral immunity plays an
essential role [37-46]. For instance, B cell deficient mice
succumb to Pneumocystis infection much more rapidly than
their immunocompetent controls [41]. In humans, cellular
immunosuppression, caused by immunosuppressive
medications and conditions such as HIV infection, play a
prominent role in the increased risk for PCP, but deficiencies of
humoral responses, such as congenital X-linked
agammaglobulinemia, may also impart an increased risk
[47,48]. Given the known importance of humoral immunity of
Pneumocystis infection in animals and humans, we
hypothesized that ambient air pollution exposures, mediated by
suppressed IgM responses to Pneumocystis Msg, would be
associated with adverse clinical outcomes. Although we found
a trend for decreased IgM responses associated with increased
length of hospital stay, the precise reasons for this finding are
unclear as length of stay is influenced by numerous factors.
IgM responses were not associated with the other measured
clinical outcomes, nor were ambient air pollutants associated
with clinical outcomes. It is important to note that the number of
clinical endpoints in our study were too few to adequately test
this clinical hypothesis.
Our study has several limitations. Ambient air pollution
exposures were estimated from daily levels measured by the
single EPA compliance air quality monitoring station in San
Francisco. Fortunately, the majority of our study participants
resided within a 3 km radius of this station such that using the
air quality data from this station to estimate subject exposures
was reasonable. Our sample size was small, and we were
unable to include a number of patients with confirmed PCP due
to lack of serum specimens drawn within 2 days of admission.
However, we are confident that the excluded cohort did not
significantly bias our study findings or alter our conclusions
given the similar clinical characteristics and comparable clinical
outcomes among included and excluded cohorts. Finally, San
Francisco experiences relatively low levels of all the criteria
ambient air pollutants. Perhaps we would have found more
pronounced immunotoxic effects and clinical outcomes in a
more polluted city.
In conclusion, elevated 3-day average PM10 and NO2
ambient air concentrations immediately prior to hospital
admission and 2 weeks prior to admission were associated
with suppressed IgM antibody responses to recombinant
Pneumocystis jirovecii major surface glycoprotein in HIV+
patients hospitalized with confirmed PCP, and active cigarette
smoking appeared to augment the immunosuppressive effects
of these pollutants. These provocative preliminary findings
suggest a mechanism of immunotoxicity by which ambient air
pollution increases host susceptibility to pulmonary infection. A
larger prospective cohort study with more precise individual-
level exposure assessments and evaluating both IgM and IgG
responses is needed to confirm these findings and to better
assess their clinical significance.
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